Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Carina Graß *Signaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.
Franziska Ober *Signaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0009-0002-0338-1227
Constanze SixtSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0009-0000-0953-9633
Bahareh Nemati MoudSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-8529-1171
Irina AntoshkinaSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0000-0003-2403-8508
Frederick EberstadtSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.
Alisa PuhachDepartment of Infection Immunology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.ORCID http://orcid.org/0000-0002-5090-8223
Antonia KeßlerSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.
Thomas J O'NeillSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0000-0003-2253-3118
Thomas SeeholzerSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany.
Jan KranichInstitute for Immunology, Faculty of Medicine, Biomedical Center Munich, Ludwig-Maximilians-Universität, Munich, Germany.
Thomas BrockerInstitute for Immunology, Faculty of Medicine, Biomedical Center Munich, Ludwig-Maximilians-Universität, Munich, Germany.ORCID http://orcid.org/0000-0001-7060-5433
Christina E ZielinskiDepartment of Infection Immunology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.ORCID http://orcid.org/0000-0002-8184-0858
Daniel KrappmannSignaling and Immunity, Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Munich - German Research Center for Environmental Health, Neuherberg, Germany. daniel.krappmann@helmholtz-munich.de.ORCID http://orcid.org/0000-0001-7640-3234
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) SFB 1054 (ID 210592381) A04Deutsche Forschungsgemeinschaft (German Research Foundation) SFB 1335 (ID 210592381) P07Deutsche Krebshilfe (German Cancer Aid) 70115440
6 · The paper itself
Abstract
The CARD11-BCL10-MALT1 (CBM) complex drives NF-κB signaling and MALT1 protease activation after T cell receptor (TCR) stimulation, forming a central signaling hub in adaptive immunity. Both linear ubiquitin chain assembly complex (LUBAC), consisting of HOIP, HOIL-1 and SHARPIN, and TRAF6 interact with the CBM complex. Still, the coordinated activity of these E3 ligases in controlling CBM activity remains elusive. Here we demonstrate that LUBAC, unlike TRAF6, is largely dispensable for TCR-induced NF-κB activation in human CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
LUBAC modulates CBM complex functions downstream of TRAF6 in T cells. · full record | OpenQuestion